Loading organizations...
Key people at CM Capital.
C.M. Capital Corporation (CMC) provides investment insights and opportunities across diverse asset classes, focusing on real estate and, through its subsidiary C.M. Capital Advisors, alternative investments like venture capital, private equity, and hedge funds. The firm’s strategy is built upon a foundation of extensive investment management experience, offering comprehensive and tailored solutions.
The company originated in 1969 to oversee the U.S. real estate investments of the Cha family, whose broader Cha Group was founded in 1949 by Dr. Cha Chi Ming. This initial role as a family office cultivated a unique perspective, guiding its expansion into wider investment services. Johnson M.D. Cha currently leads as Chairman.
CMC primarily serves the Cha Family and its affiliated Cha Group, extending its sophisticated investment advisory to individual clients. The firm envisions an ongoing expansion of its global investment reach, continually strengthening relationships with funds and managers to apply its deep expertise in navigating markets for long-term capital preservation and growth.
Key people at CM Capital.
CM Capital has 5 tracked investments across 3 companies. The latest tracked deal is $200.0M Series C in Tuya in July 2018.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 24, 2018 | Tuya | $200.0M Series C | — | Broadband Capital, CICC Capital, Future Fund, NEA, Quadrille Capital |
| Mar 1, 2012 | ThreatMetrix | $18.0M Series D | August Capital | Canaan Partners, InterWest, John Scull, Tenaya Capital, U.S. Venture Partners |
| May 25, 2011 | Pathway Therapeutics | $7.5M Other Equity | CM Capital, GBS Venture Partners | — |
| Oct 1, 2010 | ThreatMetrix | $12.0M Series C | Tenaya Capital | Amara VC, Andreessen Horowitz, Javelin Venture Partners, Morgenthaler Ventures, Osage University Partners, Plug & Play Ventures, True Ventures, U.S. Venture Partners, Y Combinator, Trammell Venture Partners |
| Aug 10, 2010 | Pathway Therapeutics | $4.5M Series A Extension | CM Capital, GBS Venture Partners | Breast Cancer Research Trust, NEW Zealand Growth Capital Partners, Trans Tasman Commercialisation Fund |
